Giorgio Giannattasio

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Michael Manning, John D. Anderson, Emel Aygören‐Pürsün, Laurence Bouillet et autres

de, fr, ca, hu, cz, us, es, il, it, bg, pl, ch (code pays fourni par la source)

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Ralf Gold, Ernst‐Wilhelm Radue, Gavin Giovannoni, Krzysztof W. Selmaj et autres

OBJECTIVE: SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. We report final results of SELECTED. METHODS: Eligible participants who completed 1-2 years of daclizumab …

de, ch, gb, pl, cz, es, us (code pays fourni par la source)

Utilization, Effectiveness and Safety of Daclizumab Beta in the Real World: Interim Analysis of the Observational ZEUS Study in Germany (P6.384)

Tjalf Ziemssen, Ulrich Freudensprung, Kirsi Taipale, Giorgio Giannattasio

To describe outcomes from an interim analysis of the non-interventional ZEUS Study.

de, ch, us (code pays fourni par la source)

Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study (P6.390)

Ralf Gold, Ernst‐Wilhelm Radue, Gavin Giovannoni, Krzysztof W. Selmaj et autres

To report long-term safety and efficacy of daclizumab beta in participants with relapsing MS in SELECTED.

de, ch, gb, pl, cz, es, us (code pays fourni par la source)

Matching-Adjusted Comparison of Daclizumab Beta vs Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis (P1.356)

Stephen L. Newman, Tjalf Ziemssen, Randy R. Robinson, Fan Wu et autres

Compare efficacy outcomes with daclizumab beta 150 mg subcutaneous every 4 weeks vs fingolimod 0.5 mg once daily in study participants with relapsing-remitting multiple sclerosis (RRMS) using matching-adjusted comparison (MAC).

de, us (code pays fourni par la source)

PO114 Neda achievement by time interval with daclizumab

Gavin Giovannoni, Ludwig Kappos, Eva Havrdová, Bhupendra Khatri et autres

Background Significantly more DECIDE patients receiving subcutaneous daclizumab HYP (daclizumab) 150 mg achieved no evidence of disease activity (NEDA) vs intramuscular interferon beta-1a (IFNβ1a) 30 µg over 96 weeks. Early residual disease activity (from pretreatment epoch) present while a new therapy reaches …

gb, ch, cz, us (code pays fourni par la source)

Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta

Gavin Giovannoni, Heinz Wiendl, Benjamin P. Turner, Kimberly Umans et autres

Background: Reversible lymphocyte count reductions have occurred following daclizumab beta treatment for relapsing–remitting multiple sclerosis. Objective: To analyse total and differential lymphocyte levels and relationship with infection status. Methods: In DECIDE, blood samples were collected at 12-week intervals from daclizumab beta- ( …

gb, de, us (code pays fourni par la source)

A Bayesian Random Effects Mixed Treatment Comparison of Daclizumab Versus Other Disease Modifying Treatments for Relapsing-Remitting Multiple Sclerosis (P6.370)

Craig Wakeford, RICHARD V. BIRNIE, Robert F. Wolff, Elizabeth T. Kinter et autres

Evaluate the clinical effectiveness and safety of daclizumab HYP (daclizumab), a structurally distinct form of daclizumab, relative to other EMA-approved disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis (RRMS).

us, gb (code pays fourni par la source)

Absence de signes d’activité de la maladie selon la période avec un traitement par daclizumab versus interféron bêta-1a dans l’étude DECIDE

Gavin Giovannoni, Ludwig Kappos, Eva Havrdová, Steven J. Greenberg et autres

gb, cz, us (code pays fourni par la source)

No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study

Ludwig Kappos, Eva Havrdová, Gavin Giovannoni, Bhupendra Khatri et autres

Background: No evidence of disease activity (NEDA) is a composite endpoint being increasingly applied as an outcome measure in clinical trials as well as proposed for individual therapeutic decisions in multiple sclerosis (MS). Objective: Assess the proportion of patients with relapsing-remitting MS …

ch, cz, gb, us (code pays fourni par la source)

DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE

Ludwig Kappos, Eva Havrdová, Gavin Giovannoni, Bhupendra Khatri et autres

Background As disease-activity-free status is now a viable treatment goal in relapsing multiple sclerosis (RMS), no evidence of disease activity (NEDA) is gaining increasing acceptance as an outcome measure. Objective To determine the percentage of RMS patients who achieved NEDA in the …

ch, cz, gb, us (code pays fourni par la source)

Treatment Satisfaction With Disease Modifying Therapies In Multiple Sclerosis: A Systematic Review of Studies Using The Treatment Satisfaction Questionnaire For Medication (Tsqm)

Jie Hua Cecilia Ting, Y Liu, Jennifer Petrillo, Giorgio Giannattasio et autres

us, ch (code pays fourni par la source)